✉  info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Vaccine Adjuvants Market Research Report Information By Type (Pathogen Component, Particulate Adjuvants, Others), By Route of Administration (Oral, Intramuscular, Subcutaneous, Intradermal), By End-User (Pediatric, Adult), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032


ID: MRFR/Pharma/0592-HCR | 110 Pages | Author: Rahul Gotadki| April 2024




Vaccine Adjuvants Market Segmentation


Vaccine Adjuvants Type Outlook (USD Billion, 2018-2030)




  • Pathogen Components




  • Particulate Adjuvants




  • Others




Vaccine Adjuvants Route of Administration Outlook (USD Billion, 2018-2030)




  • Oral




  • Intramuscular




  • Subcutaneous




  • Intradermal




Vaccine Adjuvants End User Outlook (USD Billion, 2018-2030)




  • Pediatric




  • Adult




Vaccine Adjuvants Regional Outlook (USD Billion, 2018-2030)




  • North America Outlook (USD Billion, 2018-2030)




    • North America Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • North America Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • North America Vaccine Adjuvants by End User




      • Pediatric




      • Adult






    • US Outlook (USD Billion, 2018-2030)




    • US Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • US Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • US Vaccine Adjuvants by End User




      • Pediatric




      • Adult






    • CANADA Outlook (USD Billion, 2018-2030)




    • CANADA Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • CANADA Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • CANADA Vaccine Adjuvants by End User




      • Pediatric




      • Adult








  • Europe Outlook (USD Billion, 2018-2030)




    • Europe Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • Europe Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • Europe Vaccine Adjuvants by End User




      • Pediatric




      • Adult






    • Germany Outlook (USD Billion, 2018-2030)




    • Germany Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • Germany Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • Germany Vaccine Adjuvants by End User




      • Pediatric




      • Adult






    • France Outlook (USD Billion, 2018-2030)




    • France Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • France Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • France Vaccine Adjuvants by End User




      • Pediatric




      • Adult






    • UK Outlook (USD Billion, 2018-2030)




    • UK Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • UK Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular Subcutaneous




      • Intradermal






    • UK Vaccine Adjuvants by End User




      • Pediatric




      • Adult






    • ITALY Outlook (USD Billion, 2018-2030)




    • ITALY Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • ITALY Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • ITALY Vaccine Adjuvants by End User




      • Pediatric




      • Adult














    • SPAIN Outlook (USD Billion, 2018-2030)




    • Spain Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • Spain Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • Spain Vaccine Adjuvants by End User




      • Pediatric




      • Adult






    • Rest Of Europe Outlook (USD Billion, 2018-2030)




    • Rest Of Europe Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • REST OF EUROPE Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • REST OF EUROPE Vaccine Adjuvants by End User




      • Pediatric




      • Adult







  • Asia-Pacific Outlook (USD Billion, 2018-2030)




    • Asia-Pacific Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • Asia-Pacific Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • Asia-Pacific Vaccine Adjuvants by End User




      • Pediatric




      • Adult






    • China Outlook (USD Billion, 2018-2030)




    • China Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • China Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • China Vaccine Adjuvants by End User




      • Pediatric




      • Adult






    • Japan Outlook (USD Billion, 2018-2030)




    • Japan Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • Japan Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • Japan Vaccine Adjuvants by End User




      • Pediatric




      • Adult






    • India Outlook (USD Billion, 2018-2030)




    • India Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • India Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • India Vaccine Adjuvants by End User




      • Pediatric




      • Adult






    • Australia Outlook (USD Billion, 2018-2030)




    • Australia Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • Australia Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • Australia Vaccine Adjuvants by End User




      • Pediatric




      • Adult






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)




    • Rest of Asia-Pacific Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • Rest of Asia-Pacific Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • Rest of Asia-Pacific Vaccine Adjuvants by End User




      • Pediatric




      • Adult








  • Rest of the World Outlook (USD Billion, 2018-2030)




    • Rest of the World Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • Rest of the World Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • Rest of the World Vaccine Adjuvants by End User




      • Pediatric




      • Adult














    • Middle East Outlook (USD Billion, 2018-2030)




    • Middle East Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • Middle East Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • Middle East Vaccine Adjuvants by End User




      • Pediatric




      • Adult






    • Africa Outlook (USD Billion, 2018-2030)




    • Africa Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • Africa Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • Africa Vaccine Adjuvants by End User




      • Pediatric




      • Adult






    • Latin America Outlook (USD Billion, 2018-2030)




    • Latin America Vaccine Adjuvants by Type




      • Pathogen Components




      • Particulate Adjuvants




      • Others






    • Latin America Vaccine Adjuvants by Route of Administration




      • Oral




      • Intramuscular




      • Subcutaneous




      • Intradermal






    • Latin America Vaccine Adjuvants by End User




      • Pediatric




      • Adult





















Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

Table of Contents

1 Report Prologue

2 Market Introduction

2.1 Introduction

2.2 Scope of Study

2.3 Research Objective

2.4 Assumptions & Limitations

2.4.1 Assumptions

2.4.2 Limitations

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4 Market Dynamics

4.1 Drivers

4.2 Restraints

5 Market Factor Analysis

5.1 Porter’s Five Forces Model

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

6. Global Vaccines Adjuvants Market, by Type

6.1 Pathogen Components

6.2 Particulate Adjuvants

6.3 Others

7. Global Vaccines Adjuvants Market, by Route of Administration

7.1 Oral

7.2 Intramuscular

7.3 Subcutaneous

7.4 Intradermal

8. Global Vaccines Adjuvants market, by End User

8.1 Pediatric

8.2 Adults

9. Global Vaccines Adjuvants Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 UK

9.3.1.3 France

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of Middle East & Africa

10 Competitive Landscape

10.1 Introduction

10.2 Market share Analysis

10.3 Key Development & Strategies

11 Company Profile

11.1 VaxLiant LLC.

11.1.1 Overview

11.1.2 Product/Business Segment Overview

11.1.3 Financial Updates

11.1.4 Key Developments

11.2 Vaxine Pty Ltd

11.2.1 Overview

11.2.2 Product/Business Segment Overview

11.2.3 Financial Updates

11.2.4 Key Developments

11.3 Aphios Corporation

11.3.1 Overview

11.3.2 Product/Business Segment Overview

11.3.3 Financial Updates

11.3.4 Key Development

11.4 Viscogel AB

11.4.1 Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Updates

11.4.4 Key Development

11.5 Sergeant Adjuvants

11.5.1 Overview

11.5.2 Product/Business Segment Overview

11.5.3 Financial Updates

11.5.4 Key Developments

11.6 Sigma-Aldrich Co. LLC.

11.6.1 Overview

11.6.2 Product/Business Segment Overview

11.6.3 Financial Updates

11.6.4 Key Developments

11.7 CureVac AG

11.7.1 Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financial Updates

11.7.4 Key Developments

11.8 CSL Limited

11.8.1 Overview

11.8.2 Product/Business Segment Overview

11.8.3 Financial Updates

11.8.4 Key Developments

11.9 OZ Biosciences

11.9.1 Overview

11.9.2 Product/Business Segment Overview

11.9.3 Financial Updates

11.9.4 Key Developments

11.9 Others

12 Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Vaccine Industry

13 Appendix

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Press Release
pr-img
Vaccine Adjuvants Market is Expected to Grow at a CAGR of 1.9% by 2030
Logo
Dmca Cloudflare ssl
Paypal footer Ssl
Services Industry Expertise Consulting Services Articles How To Order FAQs
Our Company About US Careers Contact Us Terms & Conditions Privacy Policy
Banking Partners
Amex Mastercard1
Razerpay
Hdfcbank
Visa
✉  info@marketresearchfuture.com
📞  +1 (855) 661-4441(US)
📞  +44 1720 412 167(UK)

© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)